Natural peptide · 70 amino acids · 7,649 Da

IGF-1 (mecasermin) studies and research data

PepBank has 52 IGF-1 studies with results. 46 of them gave IGF-1, with 415 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 415 results and 583 papers. Newer studies from Europe PMC

Results in people

399

96% of 415 results

Results in animals

3% of 415 results

Results in lab cells

under 1% of 415 results

From computer models

0% of 415 results

The molecule

IGF-1 identity

Identifiers, parent molecule, targets and development stage, from curated data.

IGF-1 is a 70-residue growth factor with three disulfide bridges. Recombinant mecasermin has the same amino-acid sequence as endogenous human IGF-I. Increlex is an approved medicine for specific severe childhood IGF-I deficiency disorders. It is distinct from IGF-1 LR3, DES analogues and MGF. The literature query covers administered recombinant IGF-I and IGF-I/IGFBP-3 complex treatments.

Kind: Natural peptide · 70 residues
Identifiers: UniProtP05019 (opens in a new tab)ChEMBLCHEMBL1201716 (opens in a new tab)UNII7GR9I2683O (opens in a new tab)DrugBankDB01277 (opens in a new tab)CAS68562-41-467763-96-6
Development: Approved in the US and EU (Increlex, 2005)Increlex: Eton Pharmaceuticals (current US labeler)FDA records original Increlex approval on 2005-08-30, BLA021839. DailyMed identifies Eton Pharmaceuticals as the current US labeler. FDA identifies Iplex as a separate mecasermin rinfabate product, BLA021884. FDA records Iplex approval on 2005-12-12 and discontinued marketing status. Iplex remains within the treatment literature scope. It is not an alias for free mecasermin. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Insulin-like growth factor 1 receptorIGF1RP08069 (opens in a new tab)	Agonist	knownSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

70 amino acids · 3 disulfide bonds

H-

GPETLCGAEL

VDALQFVCGD

RGFYFNKPTG

YGSSSRRAPQ

TGIVDECCFR

SCDLRRLEMY

CAPLKPAKSA

-OH

Properties

From identity sources

Formula: C₃₃₁H₅₁₂N₉₄O₁₀₁S₇
Molecular weight: 7,649 g/mol

GSRS UNII 7GR9I2683O(opens in a new tab)retrieved 2026-10-13
UniProt P05019(opens in a new tab)retrieved 2026-10-13
Curated Increlex label(opens in a new tab)retrieved 2026-10-13

Calculated from the sequence

pKa set

Average mass: 7,648.70 Da; Sum of ExPASy residue masses + water + 3 disulfides · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 7,643.5861 Da; Sum of ExPASy residue masses + water + 3 disulfides · ExPASy FindMod
Isoelectric point (pI): 9.01; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 0.94; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.274; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 4,470 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp: ExPASy reports more than 10 % error without Trp.
Extinction coefficient, 280 nm (all Cys as cystines): 4,845 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 67.24; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 60.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.79 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.465; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 9.01Bjellqvist (ExPASy) 8.33IPC peptide 9.32IPC protein 8.57

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 9.01 · Net charge at pH 7.4: 0.94

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, 3 disulfide. Calculated, not measured.

Show as table

pH	Net charge
0	10.00
1	9.99
2	9.89
3	9.06
4	5.28
5	1.78
6	1.08
7	0.98
8	0.77
9	0.02
10	−1.72
11	−4.68
12	−7.23
13	−10.54
14	−11.81

Composition

Hydrophobic24% (17)A I L M V
Aromatic10% (7)F Y
Positive13% (9)K R
Negative11% (8)D E
Polar16% (11)N Q S T
Special26% (18)C G P

70 residues. Each residue counts in one class; F and W count as aromatic.

A Ala6 · 9%

I Ile1 · 1%

L Leu6 · 9%

M Met1 · 1%

V Val3 · 4%

F Phe4 · 6%

W Trp0 · 0%

Y Tyr3 · 4%

H His0 · 0%

K Lys3 · 4%

R Arg6 · 9%

D Asp4 · 6%

E Glu4 · 6%

N Asn1 · 1%

Q Gln2 · 3%

S Ser5 · 7%

T Thr3 · 4%

C Cys6 · 9%

G Gly7 · 10%

P Pro5 · 7%

3D structure

PredictedAlphaFold DB · P05019

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.027
μH, best 11-residue window: 0.465
Arrow direction: 82°
Residues: 1–54 of 70 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	G	0°	0.48
2	P	100°	0.12
3	E	200°	-0.74
4	T	300°	-0.05
5	L	40°	1.06
6	C	140°	0.29
7	G	240°	0.48
8	A	340°	0.62
9	E	80°	-0.74
10	L	180°	1.06
11	V	280°	1.08
12	D	20°	-0.90
13	A	120°	0.62
14	L	220°	1.06
15	Q	320°	-0.85
16	F	60°	1.19
17	V	160°	1.08
18	C	260°	0.29
19	G	0°	0.48
20	D	100°	-0.90
21	R	200°	-2.53
22	G	300°	0.48
23	F	40°	1.19
24	Y	140°	0.26
25	F	240°	1.19
26	N	340°	-0.78
27	K	80°	-1.50
28	P	180°	0.12
29	T	280°	-0.05
30	G	20°	0.48
31	Y	120°	0.26
32	G	220°	0.48
33	S	320°	-0.18
34	S	60°	-0.18
35	S	160°	-0.18
36	R	260°	-2.53
37	R	0°	-2.53
38	A	100°	0.62
39	P	200°	0.12
40	Q	300°	-0.85
41	T	40°	-0.05
42	G	140°	0.48
43	I	240°	1.38
44	V	340°	1.08
45	D	80°	-0.90
46	E	180°	-0.74
47	C	280°	0.29
48	C	20°	0.29
49	F	120°	1.19
50	R	220°	-2.53
51	S	320°	-0.18
52	C	60°	0.29
53	D	160°	-0.90
54	L	260°	1.06

Results by area

IGF-1 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

52 of 583 studies have results (8.9%), published 1987 to 2019. Top row: every study. Bottom row: studies with results about IGF-1 (mecasermin), by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies583 in all, 1986 to 2026

Studies with results52 in all, 1987 to 2019

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

IGF-1 studies on blood sugar

74 results · people 74 · animals 0 · lab 0

Top 3 of 74 results

In adolescents with IDDM, adding rhIGF-I to insulin therapy reduced HbA1c versus placebo plus insulin therapy.Lancet, 1997
In type 1 diabetes, added rhIGF-I lowered long-term blood sugar more than intensified insulin alone.Diabetes care, 1999
In GH-deficient young adults, rhIGF-I increased glucose production by the liver from baseline.The Journal of clinical endocrinology and metabolism, 2000

IGF-1 studies on growth hormone and growth

66 results · people 55 · animals 8 · lab 3

Top 5 of 66 results

In elderly women, serum IGF-I increased in all groups, including both rhIGF-I groups.The Journal of clinical endocrinology and metabolism, 1995
In adolescents with IDDM receiving insulin therapy, rhIGF-I did not change circulating IGF-binding protein 1 compared with placebo.Lancet, 1997
In children with GH receptor deficiency, rhIGF-I increased growth rate, sustained over therapy.The Journal of clinical endocrinology and metabolism, 1995
In children with GH receptor deficiency, rhIGF-I did not alter serum IGF-binding protein-3 concentrations.The Journal of clinical endocrinology and metabolism, 1995
In healthy volunteers, neither IGF-I dose influenced binding protein-3 concentrations compared with saline control.The Journal of clinical endocrinology and metabolism, 1994

IGF-1 studies on bones and joints

52 results · people 50 · animals 2 · lab 0

Top 3 of 52 results

In women with anorexia nervosa, spinal bone density increased more with rhIGF-I than placebo in the factorial analysis.The Journal of clinical endocrinology and metabolism, 2002
In women with anorexia nervosa, serum PTH was unchanged in both rhIGF-I groups compared with placebo.The Journal of clinical endocrinology and metabolism, 1996
In fasting women, rhIGF-I increased osteocalcin, with higher levels than placebo at treatment end.The Journal of clinical investigation, 1995

IGF-1 studies on side effects

47 results · people 47 · animals 0 · lab 0

Top 5 of 47 results

In type 1 diabetes, low blood sugar occurred similarly with added rhIGF-I and insulin alone.Diabetes care, 1999
In ALS patients, significant side effects were similar with low-dose rhIGF-I, high-dose rhIGF-I, and placebo.Neurology, 1997
In adolescents with IDDM, retinal photographs showed no adverse events during the rhIGF-I trial.Lancet, 1997
In children receiving rhIGF-I, fat tissue enlargement occurred at injection sites.The Journal of clinical endocrinology and metabolism, 2007
Obese diabetic patients had a fast heartbeat during rhIGF-I treatment.Diabetes, 1994

IGF-1 studies on blood levels and clearance

31 results · people 31 · animals 0 · lab 0

Top 5 of 31 results

In women with anorexia nervosa, IGF-I levels increased with high-dose rhIGF-I.The Journal of clinical endocrinology and metabolism, 1996
In preterm infants, the complex raised serum IGF-I above predicted natural levels.Pediatric research, 2013
In patients with type II diabetes, IGF-I concentrations increased during rhIGF-I treatment and remained above normal levels.Diabetes, 1996
IGF-I increased blood IGF-I levels in postmenopausal women.The Journal of clinical endocrinology and metabolism, 1993
In preterm infants, half of IGF-I samples during complex infusion reached the target range.Pediatric research, 2013

IGF-1 studies on metabolism and nutrition

27 results · people 27 · animals 0 · lab 0

Top 5 of 27 results

In GH-deficient young adults, rhIGF-I increased protein synthesis from baseline.The Journal of clinical endocrinology and metabolism, 2000
IGF-I initially did not change beta-hydroxybutyrate in fasted normal men.The Journal of clinical investigation, 1993
In healthy adults, rhIGF-I and insulin similarly reduced fat oxidation rates.The Journal of clinical investigation, 1994
In elderly women, high-dose rhIGF-I increased nitrogen retention.The Journal of clinical endocrinology and metabolism, 1995
In fasted normal males, higher IGF-I doses reduced beta-hydroxybutyrate.The Journal of clinical endocrinology and metabolism, 1992

IGF-1 studies on weight and appetite

24 results · people 21 · animals 3 · lab 0

Top 5 of 24 results

In elderly women, fat mass decreased in all groups, including both rhIGF-I groups.The Journal of clinical endocrinology and metabolism, 1995
In adolescents with IDDM receiving insulin therapy, rhIGF-I did not change body-mass index compared with placebo.Lancet, 1997
In children with GH insensitivity, the spleen grew rapidly during early IGF-I treatment.The Journal of clinical endocrinology and metabolism, 2001
In children with GH insensitivity, kidneys grew rapidly during early IGF-I treatment.The Journal of clinical endocrinology and metabolism, 2001
In rats, hIGF-I produced body weight gain similar to hGH infusion.Endocrinology, 1989

IGF-1 studies on kidneys and bladder

20 results · people 20 · animals 0 · lab 0

Top 3 of 20 results

In acute kidney failure, rhIGF-I did not improve kidney filtration more than placebo.Kidney international, 1999
In kidney transplant recipients, day 7 kidney clearance did not differ between IGF‑1 and placebo.Kidney international, 2003
In adolescents with IDDM, kidney filtration assessments showed no adverse events during the rhIGF-I trial.Lancet, 1997

IGF-1 studies on muscles and tendons

16 results · people 16 · animals 0 · lab 0

Top 5 of 16 results

In elderly women, nitrogen balance increased with low-dose rhIGF-I after one week, as in all treatment groups.The American journal of physiology, 1997
In healthy men, tendon collagen production was higher in the IGF-I leg than in the saline-injected control leg.Scandinavian journal of medicine & science in sports, 2013
In elderly women, nitrogen balance increased with mid-dose rhIGF-I after one week, as in all treatment groups.The American journal of physiology, 1997
In healthy men, the collagen production marker PINP was higher around the IGF-I tendon than around the saline-injected control tendon.Scandinavian journal of medicine & science in sports, 2013
In elderly women, nitrogen balance increased with high-dose rhIGF-I after one week, as in all treatment groups.The American journal of physiology, 1997

IGF-1 studies on brain and nerves

12 results · people 12 · animals 0 · lab 0

Top 3 of 12 results

In ALS patients, disease progression did not differ significantly between rhIGF-I and placebo.Neurology, 1998
In ALS patients, high-dose rhIGF-I slowed worsening of function by 26% compared with placebo.Neurology, 1997
In multiple sclerosis patients, active lesion frequency did not differ between rhIGF-1 treatment and baseline periods.Multiple sclerosis, 2002

IGF-1 studies on sex hormones and fertility

12 results · people 12 · animals 0 · lab 0

Top 3 of 12 results

In very young boys with Laron syndrome, IGF-I did not change gonadotrophin levels.European journal of endocrinology, 1998
In very young boys with Laron syndrome, IGF-I did not change androgen levels.European journal of endocrinology, 1998
In very young boys with Laron syndrome, IGF-I did not change the gonads.European journal of endocrinology, 1998

IGF-1 studies on cholesterol and blood fats

11 results · people 11 · animals 0 · lab 0

Top 3 of 11 results

In GH-deficient young adults, rhIGF-I increased lipid oxidation less than rhGH.The Journal of clinical endocrinology and metabolism, 2000
In healthy adults, rhIGF-I and insulin similarly reduced free fatty acid levels.The Journal of clinical investigation, 1994
IGF-I initially did not change free fatty acids in fasted normal men.The Journal of clinical investigation, 1993

IGF-1 studies on daily life and fitness

7 results · people 7 · animals 0 · lab 0

Top 5 of 7 results

In patients with AIDS wasting, rhIGF-1 alone did not improve knee muscular strength.Annals of internal medicine, 1996
In patients with ALS, IGF‑1 did not change muscle testing scores more than placebo.Neurology, 2008
In patients with AIDS wasting, rhIGF-1 alone did not improve quality of life.Annals of internal medicine, 1996
In GH-deficient young adults, rhIGF-I did not change isokinetic muscle strength from baseline.The Journal of clinical endocrinology and metabolism, 2000
In patients with ALS, functional score changes did not differ between IGF‑1 and placebo.Neurology, 2008

IGF-1 studies on heart and blood vessels

4 results · people 4 · animals 0 · lab 0

4 results

Obese diabetic patients had low blood pressure when standing during rhIGF-I treatment.Diabetes, 1994
In healthy volunteers, low-dose IGF-I infusion did not affect forearm blood flow compared with saline control.The Journal of clinical endocrinology and metabolism, 1994
Higher IGF-I doses caused low blood pressure when standing in some postmenopausal women.The Journal of clinical endocrinology and metabolism, 1993
In healthy volunteers, high-dose IGF-I increased forearm blood flow by 68% versus control.The Journal of clinical endocrinology and metabolism, 1994

IGF-1 studies on mood, stress and behavior

3 results · people 3 · animals 0 · lab 0

3 results

In girls studied for Rett syndrome, anxiety measures improved during the open-label mecasermin extension.Proceedings of the National Academy of Sciences of the United States of America, 2014
In girls studied for Rett syndrome, reversal of a brain-wave asymmetry supported the mood and anxiety improvements during mecasermin treatment.Proceedings of the National Academy of Sciences of the United States of America, 2014
In girls studied for Rett syndrome, mood measures improved during the open-label mecasermin extension.Proceedings of the National Academy of Sciences of the United States of America, 2014

IGF-1 studies on receptors and cell signals

3 results · people 3 · animals 0 · lab 0

3 results

In healthy volunteers, epinephrine responded similarly to IGF I and insulin.The New England journal of medicine, 1987
In healthy volunteers, norepinephrine responded similarly to IGF I and insulin.The New England journal of medicine, 1987
In healthy volunteers, cortisol responded similarly to IGF I and insulin.The New England journal of medicine, 1987

IGF-1 studies on pain

2 results · people 2 · animals 0 · lab 0

2 results

Obese diabetic patients had joint pain during rhIGF-I treatment.Diabetes, 1994
Obese diabetic patients had muscle pain during rhIGF-I treatment.Diabetes, 1994

IGF-1 studies on survival and serious illness

2 results · people 2 · animals 0 · lab 0

2 results

In patients with ALS, survival without tracheostomy did not differ between IGF‑1 and placebo.Neurology, 2008
In acute kidney failure, 12 patients died in each group within 28 days.Kidney international, 1999

IGF-1 studies on immune system and inflammation

1 result · people 1 · animals 0 · lab 0

1 result

In patients with AIDS wasting, immune function did not improve in any group, including rhIGF-1 alone.Annals of internal medicine, 1996

IGF-1 studies on lungs and breathing

1 result · people 1 · animals 0 · lab 0

1 result

In girls studied for Rett syndrome, breathing pauses improved during the open-label mecasermin extension.Proceedings of the National Academy of Sciences of the United States of America, 2014

Trials and papers

IGF-1 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

52 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 52)

25 of 52 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

200020102020

Ph 2/3
Long-Term Treatment With rhIGF-1 in GHIS
NCT00571727
20 May 1991 to 15 Dec 2011
Ph 2/3
Assessment of Mechanisms of Improved Wound Healing
NCT00673309
Jul 2000 to Apr 2013
Ph 3
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
NCT00035815
Jun 2003 to Dec 2007
Ph 3
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
NCT00125164
Mar 2004 to Jul 2008
Ph 4
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437
Nov 2004 to Apr 2007
Ph 2/3
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
NCT00125190
Jul 2005 to Jan 2009
Ph 3
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
NCT00330668
Nov 2005 to Mar 2010
Terminated
Terminated
Ph 1/2
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
NCT00516386
Mar 2007 to Dec 2008
Ph 2
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
NCT00572156
Dec 2007 to Mar 2012
Terminated
Terminated
Ph 2
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
NCT00577577
Dec 2007 to 29 Dec 2008

Browse all 52 matching trials in the list below

25 trials · 1 ongoing · 17 completed · 6 stopped early · 19 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01618513

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

University of Aarhusn = 84Jun 2012 to Jan 2017

Acromegaly

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Status unknownPhase 4NCT01052623

Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)

Johann Wolfgang Goethe University Hospitaln = 24Jan 2010 to est. Sept 2012

Ataxia Telangiectasia · Growth Failure

Trial page ClinicalTrials.govUpdated 5 Jul 2010

CompletedPhase 4NCT00151437

Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Pfizern = 30Nov 2004 to Apr 2007

Acromegaly

Trial page ClinicalTrials.govUpdated 24 Apr 2008

CompletedPhase 2/3Results postedNCT00571727

Long-Term Treatment With rhIGF-1 in GHIS

Ipsenn = 9220 May 1991 to 15 Dec 2011

Growth Hormone Insensitivity Syndrome

Trial page ClinicalTrials.govUpdated 6 Jul 2023

CompletedPhase 2/3Results postedNCT00673309

Assessment of Mechanisms of Improved Wound Healing

The University of Texas Medical Branch, Galvestonn = 644Jul 2000 to Apr 2013

Burns

Trial page ClinicalTrials.govUpdated 3 Jul 2023

CompletedPhase 3Results postedNCT01301183

Effects of Anorexia Nervosa on Peak Bone Mass

Massachusetts General Hospitaln = 75Feb 2011 to Mar 2020

Anorexia Nervosa

Trial page ClinicalTrials.govUpdated 13 Jul 2021

TerminatedPhase 3Results postedNCT00330668

Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

Ipsenn = 114Nov 2005 to Mar 2010

Growth Disorders

Trial page ClinicalTrials.govUpdated 14 Aug 2020

CompletedPhase 2/3Results postedNCT00125190

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

Ipsenn = 45Jul 2005 to Jan 2009

Insulin-Like Growth Factor-1 Deficiency · Growth Disorders

Trial page ClinicalTrials.govUpdated 27 Jul 2020

CompletedPhase 3Results postedNCT00125164

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Ipsenn = 137Mar 2004 to Jul 2008

Growth Disorders · Insulin-Like Growth Factor-1 Deficiency

Trial page ClinicalTrials.govUpdated 18 Sept 2019

TerminatedPhase 2/3Results postedNCT00764699

Effect of Increlex® on Children With Crohn Disease

Nationwide Children's Hospitaln = 3Oct 2008 to May 2010

Crohn Disease

Trial page ClinicalTrials.govUpdated 2 Mar 2018

CompletedPhase 3NCT01020955

Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)

Karolinska University Hospitaln = 14Oct 2009 to Nov 2011

Diabetes

Trial page ClinicalTrials.govUpdated 7 Apr 2015

CompletedPhase 3Results postedNCT00035815

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Mayo Clinicn = 330Jun 2003 to Dec 2007

Amyotrophic Lateral Sclerosis

Trial page ClinicalTrials.govUpdated 15 Feb 2013

CompletedPhase 2/3NCT00368173

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Insmed Incorporated

Growth Hormone Insensitivity Syndrome (GHIS) · Laron Syndrome

Trial page ClinicalTrials.govUpdated 13 Sept 2012

Active, not recruitingPhase 2NCT03253263

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

OHB Neonatology Ltd.n = 2959 May 2019 to est. 21 Jan 2028

Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Intraventricular Hemorrhage · Retinopathy of Prematurity (ROP)

Trial page ClinicalTrials.govUpdated 3 Aug 2026

TerminatedPhase 1/2Results postedNCT00684957

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Columbia Universityn = 5Jan 2008 to Oct 2012

Growth Hormone Deficiency

Trial page ClinicalTrials.govUpdated 17 Jul 2024

CompletedPhase 1/2Results postedNCT02636270

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Children's Hospital Medical Center, Cincinnatin = 721 Dec 2015 to 1 Dec 2022

Short Stature

Trial page ClinicalTrials.govUpdated 28 Feb 2024

TerminatedPhase 2Results postedNCT01970345

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Icahn School of Medicine at Mount Sinain = 3May 2014 to 13 Sept 2017

Autism Spectrum Disorder

Trial page ClinicalTrials.govUpdated 8 Feb 2024

TerminatedPhase 2Results postedNCT00572156

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Ipsenn = 106Dec 2007 to Mar 2012

Insulin-like Growth Factor-1 Deficiency

Trial page ClinicalTrials.govUpdated 30 Mar 2023

CompletedPhase 2Results postedNCT02386839

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

Shiren = 7626 Mar 2015 to 28 Sept 2021

Retinopathy of Prematurity (ROP)

Trial page ClinicalTrials.govUpdated 18 May 2022

CompletedPhase 2Results postedNCT01525901

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

Icahn School of Medicine at Mount Sinain = 19Feb 2012 to 23 Aug 2016

22q13 Deletion Syndrome · Phelan-McDermid Syndrome

Trial page ClinicalTrials.govUpdated 12 May 2022

TerminatedPhase 1/2Results postedNCT03041701

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Cancer Institute (NCI)n = 147 Jul 2017 to 16 Oct 2021

Rhabdomyosarcoma · Rhabdomyosarcoma, Alveolar · Rhabdomyosarcoma, Embryonal

Trial page ClinicalTrials.govUpdated 14 Apr 2022

CompletedPhase 2Results postedNCT00577577

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Insmed Incorporatedn = 69Dec 2007 to 29 Dec 2008

Myotonic Dystrophy Type 1

Trial page ClinicalTrials.govUpdated 6 Jan 2022

CompletedPhase 1/2Results postedNCT00516386

Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents

Massachusetts General Hospitaln = 16Mar 2007 to Dec 2008

Anorexia Nervosa

Trial page ClinicalTrials.govUpdated 18 Nov 2021

CompletedPhase 2Results postedNCT00720122

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa

Massachusetts General Hospitaln = 28Jul 2008 to Oct 2011

Disorder of Bone Density and Structure, Unspecified

Trial page ClinicalTrials.govUpdated 18 Nov 2021

CompletedPhase 2Results postedNCT01096784

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Shiren = 12118 Jun 2010 to 30 Mar 2016

Retinopathy of Prematurity (ROP)

Trial page ClinicalTrials.govUpdated 14 Jun 2021

254 more mention it but do not test it. They are not trials of IGF-1 (mecasermin): they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

583 studies match. Retracted studies are left out.

Showing 25 of 583 studiesquery qry_6c6d0a7c5161ad9ff70bfe06

Studies with results

52 studies in all, 16 on this page

Non-randomized trial · 1987

10 results

Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

Guler et al. 1987The New England journal of medicinen = 8cited by 328

PMID 3299085DOI 10.1056/nejm198707163170303PUB-03299085

Full text at the publisher10 results where IGF-1 (mecasermin) was given

Publisher page See results (10)

Randomized controlled trial · 1997

5 results

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

Lai et al. 1997Neurologyn = 266cited by 245

PMID 9409357DOI 10.1212/wnl.49.6.1621PUB-09409357

Full text at the publisher5 results where IGF-1 (mecasermin) was given

Publisher page See results (5)

Not a test of IGF-1 (mecasermin) alone · 1997

9 results

A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease.

Howell et al. 1997Journal of periodontologycited by 245

PMID 9444594DOI 10.1902/jop.1997.68.12.1186PUB-09444594

Full text at the publisher9 results where IGF-1 (mecasermin) was a tool, carrier or part of a combination

Publisher page See results (9)

Randomized controlled trial · 1998

2 results

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

Borasio et al. 1998Neurologyn = 183cited by 240

PMID 9710040DOI 10.1212/wnl.51.2.583PUB-09710040

Full text at the publisher2 results where IGF-1 (mecasermin) was given

Publisher page See results (2)

Randomized controlled trial · 2002

6 results

Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.

Grinspoon et al. 2002The Journal of clinical endocrinology and metabolismn = 60cited by 213

PMID 12050268DOI 10.1210/jcem.87.6.8574PUB-12050268

Rights unknown4 results where IGF-1 (mecasermin) was given (plus 2 on tools or combinations, listed separately)

Source link See results (6)

Randomized controlled trial · 2008

3 results

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Sorenson et al. 2008Neurologyn = 330cited by 188

PMID 19029516PMC2617770DOI 10.1212/01.wnl.0000335970.78664.36PUB-19029516

Rights unknown3 results where IGF-1 (mecasermin) was given

Source link See results (3)

Non-randomized trial · 1996

15 results

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.

Moses et al. 1996Diabetesn = 12cited by 186

PMID 8522066DOI 10.2337/diab.45.1.91PUB-08522066

Full text at the publisher15 results where IGF-1 (mecasermin) was given

Publisher page See results (15)

Randomized controlled trial · 1999

11 results

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.

Hirschberg et al. 1999Kidney internationaln = 72cited by 173

PMID 10354291DOI 10.1046/j.1523-1755.1999.00463.xPUB-10354291

Full text at the publisher11 results where IGF-1 (mecasermin) was given

Publisher page See results (11)

Non-randomized trial · 1989

8 results

Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.

Guler et al. 1989Proceedings of the National Academy of Sciences of the United States of American = 2cited by 168

PMID 2649897PMC287020DOI 10.1073/pnas.86.8.2868PUB-02649897

Rights unknown8 results where IGF-1 (mecasermin) was given

Source link See results (8)

Non-randomized trial · 2014

8 results

Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

Khwaja et al. 2014Proceedings of the National Academy of Sciences of the United States of American = 12cited by 163

PMID 24623853PMC3970488DOI 10.1073/pnas.1311141111PUB-24623853

Rights unknown8 results where IGF-1 (mecasermin) was given

Source link See results (8)

Randomized controlled trial · 1996

13 results

Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.

Grinspoon et al. 1996The Journal of clinical endocrinology and metabolismn = 23cited by 160

PMID 8923830DOI 10.1210/jcem.81.11.8923830PUB-08923830

Rights unknown12 results where IGF-1 (mecasermin) was given (plus 1 on natural levels, listed separately)

Source link See results (13)

Non-randomized trial · 2007

5 results

Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

Chernausek et al. 2007The Journal of clinical endocrinology and metabolismn = 76cited by 152

PMID 17192294DOI 10.1210/jc.2006-1610PUB-17192294

Rights unknown5 results where IGF-1 (mecasermin) was given

Source link See results (5)

Not a test of IGF-1 (mecasermin) alone · 1999

6 results

Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment.

Herndon et al. 1999Annals of surgerycited by 125

PMID 10235530DOI 10.1097/00000658-199905000-00014PUB-10235530

Full text at the publisher6 results where IGF-1 (mecasermin) was a tool, carrier or part of a combination

Publisher page See results (6)

Not a test of IGF-1 (mecasermin) alone · 2019

10 results

rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.

Ley et al. 2019The Journal of pediatricscited by 124

PMID 30471715PMC6389415DOI 10.1016/j.jpeds.2018.10.033PUB-30471715

Free to read · publisher termsCC BY-NC-ND10 results where IGF-1 (mecasermin) was a tool, carrier or part of a combination

Read at source See results (10)

Non-randomized trial · 1995

15 results

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.

Ghiron et al. 1995Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchn = 16cited by 108

PMID 8619364DOI 10.1002/jbmr.5650101203PUB-08619364

Full text at the publisher15 results where IGF-1 (mecasermin) was given

Publisher page See results (15)

Non-randomized trial · 1993

14 results

A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

Hartman et al. 1993The Journal of clinical investigationn = 10cited by 103

PMID 8514857PMC443305DOI 10.1172/jci116480PUB-08514857

Rights unknown14 results where IGF-1 (mecasermin) was given

Source link See results (14)

More studies

530 studies in all, 9 on this page

PubMed tag: none · 2009

SNP genotyping using the Sequenom MassARRAY iPLEX platform.

Gabriel et al. 2009Current protocols in human geneticscited by 666

PMID 19170031DOI 10.1002/0471142905.hg0212s60PUB-19170031

Full text at the publisher

Publisher page

PubMed tag: Practice Guideline · 2016

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.

Grimberg et al. 2016Hormone research in paediatricscited by 508

PMID 27884013DOI 10.1159/000452150PUB-27884013

Rights unknown

Source link

Indexing hint: Animal study · 1988

Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.

Guler et al. 1988Proceedings of the National Academy of Sciences of the United States of Americacited by 210

PMID 3387445PMC280542DOI 10.1073/pnas.85.13.4889PUB-03387445

Rights unknown

Source link

PubMed tag: Review · 2014

Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Singh et al. 2014Medical oncology (Northwood, London, England)cited by 156

PMID 24338270DOI 10.1007/s12032-013-0805-3PUB-24338270

Full text at the publisher

Publisher page

Indexing hint: Animal study · 2010

Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function.

Mariño et al. 2010Proceedings of the National Academy of Sciences of the United States of Americacited by 116

PMID 20805469PMC2941281DOI 10.1073/pnas.1002696107PUB-20805469

Rights unknown

Source link

Indexing hint: Animal study · 1986

Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I.

Scheiwiller et al. 1986Naturecited by 102

PMID 3528867DOI 10.1038/323169a0PUB-03528867

Full text at the publisher

Publisher page

Indexing hint: Animal study · 2009

Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats.

Lin et al. 2009Experimental neurologycited by 102

PMID 19332057PMC2766530DOI 10.1016/j.expneurol.2009.03.021PUB-19332057

Rights unknown

Source link

PubMed tag: none · 1992

Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast.

Kiefer et al. 1992The Journal of biological chemistrycited by 101

PMID 1377672DOI 10.1016/s0021-9258(18)42332-0PUB-01377672

Full text at the publisher

Publisher page

Indexing hint: Animal study · 1989

Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

Zapf et al. 1989Proceedings of the National Academy of Sciences of the United States of Americacited by 97

PMID 2471192PMC287231DOI 10.1073/pnas.86.10.3813PUB-02471192

Rights unknown

Source link

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

IGF-1 (mecasermin) studies: 52 papers with results

Page 1 of 2

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ · Neurology · 2008
Randomized controlled trial · 3 results
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
Lai EC · Neurology · 1997
Randomized controlled trial · 5 results
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD · Neurology · 1998
Randomized controlled trial · 2 results
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
Hirschberg R · Kidney international · 1999
Randomized controlled trial · 11 results
Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.
Acerini CL · Lancet (London, England) · 1997
Randomized controlled trial · 13 results
A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF.
Hladunewich MA · Kidney international · 2003
Randomized controlled trial · 3 results
Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
Thrailkill KM · Diabetes care · 1999
Randomized controlled trial · 8 results
Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
Grinspoon S · The Journal of clinical endocrinology and metabolism · 2002
Randomized controlled trial · 6 results
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
Grinspoon S · The Journal of clinical endocrinology and metabolism · 1996
Randomized controlled trial · 13 results
A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
Guevara-Aguirre J · The Journal of clinical endocrinology and metabolism · 1995
Randomized controlled trial · 4 results
The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women.
Thompson JL · The Journal of clinical endocrinology and metabolism · 1995
Randomized controlled trial · 13 results
Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial.
Waters D · Annals of internal medicine · 1996
Randomized controlled trial · 22 results
Effects of rhIGF-I administration on bone turnover during short-term fasting.
Grinspoon SK · The Journal of clinical investigation · 1995
Randomized controlled trial · 7 results
Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism.
Mauras N · The Journal of clinical endocrinology and metabolism · 2000
Randomized controlled trial · 25 results
Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women.
Butterfield GE · The American journal of physiology · 1997
Randomized controlled trial · 20 results
A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.
Frank JA · Multiple sclerosis (Houndmills, Basingstoke, England) · 2002
Non-randomized trial · 8 results
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD · The Journal of clinical endocrinology and metabolism · 2007
Non-randomized trial · 5 results
Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
Boulware SD · The Journal of clinical investigation · 1994
Non-randomized trial · 12 results
Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J · The Journal of clinical endocrinology and metabolism · 1997
Non-randomized trial · 15 results
Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa.
Misra M · Bone · 2009
Non-randomized trial · 6 results
Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women.
Ebeling PR · The Journal of clinical endocrinology and metabolism · 1993
Non-randomized trial · 11 results
Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.
Ghiron LJ · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1995
Non-randomized trial · 15 results
Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.
Moses AC · Diabetes · 1996
Non-randomized trial · 15 results
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.
Khwaja OS · Proceedings of the National Academy of Sciences of the United States of America · 2014
Non-randomized trial · 8 results
Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans.
Hansen M · Scandinavian journal of medicine & science in sports · 2013
Non-randomized trial · 2 results
Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.
Lieberman SA · The Journal of clinical endocrinology and metabolism · 1992
Non-randomized trial · 15 results
Recombinant human insulin-like growth factor-I increases forearm blood flow.
Copeland KC · The Journal of clinical endocrinology and metabolism · 1994
Non-randomized trial · 8 results
A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.
Hartman ML · The Journal of clinical investigation · 1993
Non-randomized trial · 14 results
Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.
Lieberman SA · The Journal of clinical endocrinology and metabolism · 1994
Non-randomized trial · 10 results
Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.
Guler HP · The New England journal of medicine · 1987
Non-randomized trial · 10 results
Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.
Backeljauw PF · The Journal of clinical endocrinology and metabolism · 2001
Non-randomized trial · 11 results
Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
Cusi K · The Journal of clinical endocrinology and metabolism · 2000
Non-randomized trial · 7 results
Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.
Jabri N · Diabetes · 1994
Non-randomized trial · 13 results
Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
Clemmons DR · The Journal of clinical endocrinology and metabolism · 1992
Non-randomized trial · 5 results
Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.
Vaccarello MA · The Journal of clinical endocrinology and metabolism · 1993
Non-randomized trial · 17 results
Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1997
Non-randomized trial · 9 results
Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety.
Ley D · Pediatric research · 2013
Non-randomized trial · 6 results
Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance).
Laron Z · European journal of endocrinology · 1998
Non-randomized trial · 13 results
Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.
Guler HP · Proceedings of the National Academy of Sciences of the United States of America · 1989
Non-randomized trial · 8 results
Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man.
Turkalj I · The Journal of clinical endocrinology and metabolism · 1992
Non-randomized trial · 16 results
Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.
Laager R · The Journal of clinical investigation · 1993
Non-randomized trial · 8 results
Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance.
Schoenle EJ · Diabetologia · 1991
Case report or series · 4 results
Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA · The Journal of clinical endocrinology and metabolism · 2000
Case report or series · 10 results
Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.
Morrow LA · The Journal of clinical endocrinology and metabolism · 1994
Case report or series · 12 results
Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
Nakae J · The Journal of clinical endocrinology and metabolism · 1998
Case report or series · 8 results
Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I.
Skottner A · Endocrinology · 1989
Animal study (in vivo) · rat · 21 results
Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
Clemmons DR · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2005
Not a test of IGF-1 (mecasermin) alone · 11 results
rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.
Ley D · The Journal of pediatrics · 2019
Not a test of IGF-1 (mecasermin) alone · 10 results
A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease.
Howell TH · Journal of periodontology · 1997
Not a test of IGF-1 (mecasermin) alone · 9 results
Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
Boonen S · The Journal of clinical endocrinology and metabolism · 2002
Not a test of IGF-1 (mecasermin) alone · 7 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Increlex · 30 Aug 2005	13 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Increlex · 2 Aug 2007	13 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S2.3) The recorded 2026 S2.3 prohibition remains pending source verification.	2026 List	wada-ama.org (opens in a new tab)
Russia	Note	National medicine registration not established in this profile.	13 Oct 2026	Not recorded

Safety outcomes

55 safety results for IGF-1 (mecasermin).

Human evidence· 55

In ALS patients, clinically significant adverse experiences were comparable with low-dose rhIGF-I, high-dose rhIGF-I, and placebo.
Randomized controlled trialn = 266
In type 1 diabetes, hypoglycemia incidence was similar with added rhIGF-I and insulin alone.
Randomized controlled trialn = 223
In ALS patients, rhIGF-I appeared safe and well tolerated.
Randomized controlled trialn = 124
In acute renal failure, 12 rhIGF-I patients and 12 placebo patients died within 28 days.
Randomized controlled trialn = 72
Deaths within 28 days after onset of treatment
12 patients
rhIGF-I group
Deaths within 28 days after onset of treatment
12 patients
placebo group
In type 1 diabetes, the 40/40 dose of rhIGF-I was well tolerated.
Randomized controlled trialn = 56
In adolescents with IDDM, retinal photographs showed no adverse events during the rhIGF-I trial.
Randomized controlled trialn = 53
In adolescents with IDDM, glomerular filtration assessments showed no adverse events during the rhIGF-I trial.
Randomized controlled trialn = 53
In adolescents with IDDM, urinary albumin assessments showed no adverse events during the rhIGF-I trial.
Randomized controlled trialn = 53

The top 24 of 55 results.

Doses studied · 75

The doses that these studies used. They are not recommendations.

0.05 mg/kg twice dailyHuman
Species
human
Route
subcutaneous
Duration
2 years
Design
Randomized controlled trial · n = 330
0.1 mg/kg/dayHuman
Species
human
Route
subcutaneous
Duration
9 months
Design
Randomized controlled trial · n = 183
100 microgram/kg desirable body weight every 12 hoursHuman
Species
human
Route
subcutaneous
Duration
up to 14 days
Design
Randomized controlled trial · n = 72
100 mg/kg twice a dayHuman
Species
human
Route
subcutaneous
Duration
6 days
Design
Randomized controlled trial · n = 43
0.10 mg/kg/dayHuman
Species
human
Route
Not reported
Duration
9 months
Design
Randomized controlled trial
40 microg/kg dailyHuman
Species
human
Route
subcutaneous
Duration
24 weeks
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
0.05 mg/kg twice daily	Human	human	subcutaneous	2 years	Randomized controlled trial · n = 330
0.1 mg/kg/day	Human	human	subcutaneous	9 months	Randomized controlled trial · n = 183
100 microgram/kg desirable body weight every 12 hours	Human	human	subcutaneous	up to 14 days	Randomized controlled trial · n = 72
100 mg/kg twice a day	Human	human	subcutaneous	6 days	Randomized controlled trial · n = 43
0.10 mg/kg/day	Human	human	Not reported	9 months	Randomized controlled trial
40 microg/kg daily	Human	human	subcutaneous	24 weeks	Randomized controlled trial

6 of 75 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000071
Peptide version: 5
Peptide hash: 31cf1b4d62f4ceb0…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256707
22 Oct 2026UpdatedData version 254535
21 Oct 2026UpdatedData version 213631
14 Oct 2026UpdatedData version 212210
14 Oct 2026CreatedData version 198207

For developers

curl -s https://pepbank.io/v1/briefs/igf-1

Evidence summary for IGF-1 (mecasermin): counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Glycemic controlMetabolic and weight	Human: 74 results from 20 studies: 10 increase, 47 decrease, 11 no significant change, 1 mixed, 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	74
Growth hormone and IGF-1Metabolic and weight	Human: 54 results from 18 studies: 11 increase, 18 decrease, 19 no significant change, 6 not reported. Strongest design: Randomized controlled trial	Animal: 8 results from 1 study: 5 increase, 1 no significant change, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 1 study: 3 not reported. Strongest design: In vitro (cells)	No results	65
Bone and jointMusculoskeletal	Human: 50 results from 11 studies: 28 increase, 4 decrease, 16 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	52
Adverse eventsWhole body	Human: 46 results from 18 studies: 8 no significant change, 38 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	46
PharmacokineticsPharmacology	Human: 31 results from 12 studies: 20 increase, 1 decrease, 7 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	31
Kidney functionKidney and urinary	Human: 20 results from 6 studies: 3 increase, 16 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	20
Protein and amino acid metabolismMetabolic and weight	Human: 18 results from 7 studies: 6 increase, 8 decrease, 4 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	18
Muscle injury and repairMusculoskeletal	Human: 14 results from 1 study: 14 increase. Strongest design: Randomized controlled trial	No results	No results	No results	14
Body compositionMetabolic and weight	Human: 13 results from 6 studies: 7 increase, 4 decrease, 1 no significant change, 1 mixed. Strongest design: Randomized controlled trial	No results	No results	No results	13
NeuroprotectionNervous system and cognition	Human: 12 results from 3 studies: 3 decrease, 8 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Sex hormones and fertilityReproductive and sexual health	Human: 12 results from 1 study: 5 increase, 2 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	12
LipidsMetabolic and weight	Human: 11 results from 6 studies: 8 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	11

Outcome group	Human	Animal	Lab	Computer model	Total
Glycemic controlMetabolic and weight	Human: 74 results from 20 studies: 10 increase, 47 decrease, 11 no significant change, 1 mixed, 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	74
Growth hormone and IGF-1Metabolic and weight	Human: 54 results from 18 studies: 11 increase, 18 decrease, 19 no significant change, 6 not reported. Strongest design: Randomized controlled trial	Animal: 8 results from 1 study: 5 increase, 1 no significant change, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 3 results from 1 study: 3 not reported. Strongest design: In vitro (cells)	No results	65
Bone and jointMusculoskeletal	Human: 50 results from 11 studies: 28 increase, 4 decrease, 16 no significant change, 2 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	52
Adverse eventsWhole body	Human: 46 results from 18 studies: 8 no significant change, 38 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	46
PharmacokineticsPharmacology	Human: 31 results from 12 studies: 20 increase, 1 decrease, 7 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	31
Kidney functionKidney and urinary	Human: 20 results from 6 studies: 3 increase, 16 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	20
Protein and amino acid metabolismMetabolic and weight	Human: 18 results from 7 studies: 6 increase, 8 decrease, 4 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	18
Muscle injury and repairMusculoskeletal	Human: 14 results from 1 study: 14 increase. Strongest design: Randomized controlled trial	No results	No results	No results	14
Body compositionMetabolic and weight	Human: 13 results from 6 studies: 7 increase, 4 decrease, 1 no significant change, 1 mixed. Strongest design: Randomized controlled trial	No results	No results	No results	13
NeuroprotectionNervous system and cognition	Human: 12 results from 3 studies: 3 decrease, 8 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Sex hormones and fertilityReproductive and sexual health	Human: 12 results from 1 study: 5 increase, 2 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	12
LipidsMetabolic and weight	Human: 11 results from 6 studies: 8 decrease, 3 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	11

Outcome group	Human	Animal	Lab	Computer model	All
Growth hormone and IGF-1Endocrine and hormones	6	–	–	–	6
All outcome groups	6	–	–	–	6